The foreword establishes that the foundation of appropriate-use information is the (electronic) package insert, and that the Product Information Summary merely supplements it. The sentence is short, but this hierarchy is the root from which every constraint in the Creation Guide branches. The prohibition on going one word beyond approved content, the obligation to include safety information without omission — both derive from here.
Reading "supplements" as "something extra that is nice to have" is a misreading of the structure. Supplementary means subordinate to a source that already exists. Exceeding the scope that source defines, contradicting it, or presenting information in a way that renders it effectively void — all of these fall outside the definition of supplementing.
01What it means for the package insert to be the "source of record"
The electronic package insert is the official record of what the national authority has approved: indications, dosage, contraindications, adverse reactions, interactions. The content of the package insert is determined by what the government approved, nothing more. No matter how well-designed a Product Information Summary may be, it cannot step outside the approved record.
Being the "source of record" carries three concrete implications. First, the approved content sets the ceiling on what may be stated — unapproved indications or dosages may not appear. Second, when the package insert is revised, the Product Information Summary must follow — if the original changes, the supplement must change with it. Third, where the Product Information Summary contradicts the package insert, the summary is wrong — the original always takes precedence.
What digitization changed, and what it did not
The transition from paper package inserts to electronic ones changed how the document is accessed. It did not change the package insert's position as the source of record. Digitization is an operational shift. The hierarchy between the package insert and the Product Information Summary remains unchanged.
02What supplementing means — and where deviation begins
To supplement means to make approved content easier to understand, or to organize information for a particular clinical audience or setting, taking the original as given. Presenting package insert content in a visual format, pulling out items relevant to a specific patient population, adding academic context to deepen understanding — these are legitimate acts of supplementing.
Deviation begins when the purpose of supplementing is exceeded. The following are typical cases.
Adding content that touches on unapproved indications
Suggesting dosages or routes outside the approved range
Failing to present safety information boxed in the package insert with equivalent prominence
Omitting contraindications, or positioning them so they are unlikely to be noticed
Each of these crosses out of legitimate supplementing. Inserting unapproved claims into a material is not supplementing the package insert — it is attempting to rewrite the limits the package insert defines.
"Not explicitly prohibited" does not mean "within the scope of supplementing." The test is whether the content is consistent with the approved record and does not contradict the package insert. This test applies even where the Guide contains no explicit rule.
03The chain of constraints the hierarchy generates
The hierarchy — package insert as original, Product Information Summary as supplement — generates constraints one by one. The most significant are as follows.
Indications and dosage are limited to approved content. Indications pending approval, or uses approved in other countries but not yet domestically approved, cannot appear in supplementary materials. What does not exist in the original cannot be created by the supplement.
Safety information from the package insert may not be omitted. Information corresponding to warnings and contraindications must be presented in the summary with equivalent treatment. What the original treats as high-priority cannot be downgraded by the supplement.
Tracking revisions is required. When the package insert is revised, the Product Information Summary must reflect the revision. A summary still based on a superseded package insert may contradict the current original.
In closing
Saying the Product Information Summary "merely supplements" is not a deprecation of its value. It is a statement of structural constraint: because an original exists, the supplement has meaning only within the scope of that original. Only with this hierarchy in place does the obligation not to exceed approved content, the obligation not to omit safety information, and the obligation to track revisions connect in a single chain of logic. The word "supplements" in the foreword is the single point from which the entire network of constraints in the Guide extends.
Case studies — the "it isn't written, so…" mindset, and how each lands
The subordinate relationship that makes the electronic PI the "original document" fixes the ceiling of what a supplement may contain at the boundary of approved fact. Two directions breach that boundary most often: using the supplement's name to quietly rewrite the original, or leaving the supplement unchanged after the original is updated. The four levels below trace those paths.
GRAY 1 — Straying from the spirit (untouched by the wording, but against the foreword's spirit)
The scheme: "The electronic PI is dense and rarely read straight through. As a supplement material, prioritising readability by front-loading the most commercially appealing indication serves the physician's convenience."
Verdict: Improving readability is a legitimate supplementary purpose. But a structure built around only the most commercially appealing indication selects from what the electronic PI treats as equal — and the overall impression the material creates diverges from the weight the original assigns. The correct approach is to cover all approved indications and then enhance understanding of specific areas, without altering the balance.
GRAY 2 — Exploiting the gap (deliberately working a loophole to invite misreading)
The scheme: "Within the approved dose range, one specific dose produced the best trial data. Highlighting it prominently as a 'recommended example' in a figure stays within the approved range — no rule is broken."
Verdict: Even within the approved dose range, steering physicians toward a single dose goes beyond supplementing the electronic PI — it actively intervenes in a dosing judgment the PI leaves to the prescriber. Framing one dose as "recommended" effectively reverses the original document's primacy. The correct approach is to present the full dose range without any visual steering toward a preferred dose.
GRAY 3 — Violating higher norms (arguably "not in the text," yet almost certainly out under the PMD Act, Fair Advertising Standards, and the JPMA Code)
The scheme: "The product is already approved for a broader indication overseas, and a domestic supplemental application is under review. Framing it as 'reference information on the pending indication' keeps it within the supplementary structure."
Verdict: Including information about a domestically unapproved indication falls under PMD Act Article 68's prohibition of promoting unapproved efficacy, regardless of whether an application is pending. "Supplementary" means supplementing approved fact — the moment unapproved content enters, the material has left the supplement framework by definition. No information about unapproved domestic indications may appear in any material.
BLACK — Breaching the explicit text (a plain violation of the provision itself)
The scheme: "A new adverse event was added to the electronic PI, but updating our material takes several weeks. If we keep distributing the old version while verbally noting 'this is under revision,' we minimise disruption in the field."
Verdict: Continuing to distribute an outdated material after the electronic PI has been updated breaks the consistency between original and supplement that the Guidelines explicitly require. A verbal caveat cannot amend the printed content of a distributed material. Once the electronic PI is revised, the old version must be withdrawn immediately and a revised material distributed without delay.
Improper intent by implication — three scopes of "insinuating" without stating it
The hierarchy in which the electronic package insert (ePI) is the primary document and the Product Information Summary (PIS) is its supplement can be silently inverted through three operations: dropping a single qualifying modifier, placing adjacent sentences so they bridge the domestic approval boundary, and relegating the ePI to the final page of a document whose body generates its own framing.
Implication 1 — Local: carried in a single word or sentence
How it is built: "Drop the limiting qualifier from the approved indication. Instead of 'used primarily for the treatment of X,' write 'a treatment for X,' removing the word 'primarily' that bounds the approved scope."
Intent that can be read: Removing a single modifier that signals a restricted indication broadens the implied scope of use without naming any unapproved indication. The approved boundary disappears in one word.
Verdict: Omitting the qualifying modifier that delimits the approved indication is a one-word operation that expands the implied scope. A PIS must reproduce the language of the ePI with precision; selective deletion of limiting qualifiers is not permitted.
Implication 2 — Adjacent: read across neighboring clauses
How it is built: "On the same page, place 'The approved indications in Japan are as follows' immediately above 'Overseas clinical guidelines recommend this drug for the following conditions,' with no statement that those conditions are not approved domestically."
Intent that can be read: The sequential placement creates an implied equivalence: domestic approval followed by overseas reinforcement. No off-label indication is named; yet the juxtaposition strongly suggests that the overseas conditions are a natural extension of domestic use.
Verdict: Placing domestic approval data and overseas guideline recommendations on the same page without a clear disclaimer of domestic non-approval bridges the regulatory boundary through proximity alone. Any reference to overseas guidance must explicitly state the domestic approval status and mark the information as outside the approved scope.
Implication 3 — Whole-context: arising from the document as a whole
How it is built: "Structure the body of the PIS across three chapters — efficacy data, dose rationale, patient QoL evidence — and place 'Indications and Dosage (from the ePI)' in a boxed table on the final page only."
Intent that can be read: By the time the reader reaches the ePI table, three chapters of contextualising content have already shaped interpretation. The document does not supplement the ePI; it frames the ePI as a brief addendum to a richer clinical story the manufacturer has constructed.
Verdict: Positioning the ePI-derived approval information as a final-page appendix structurally inverts the primary–supplementary relationship. The approved indications and dosage must anchor the document from the outset; subsequent chapters may elaborate within that anchor, never reframe it.